$1.31 4%
AKBA Stock Price vs. AI Score (Last 150 days)
Data gathered: July 16

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.

Akebia Therapeutics
Price $1.31
Target Price Sign up
Volume 2,940,000
Market Cap $264M
Year Range $0.86 - $2.24
Dividend Yield 0%
Revenue per Employee $438,282
Industry Biotechnology

In the news

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '2432M12M20M-18M-5.9M-0.090
Q4 '2356M19M38M610,00010M0.003
Q3 '2342M18M24M-14M-4M-0.080
Q2 '2356M17M39M-11M4,000-0.060
Q1 '2340M20M21M-27M-16M-0.140

Insider Transactions View All

Dahan Michel filed to sell 672,092 shares at $1.3.
May 14 '24
Hadas Nicole R. filed to sell 651,243 shares at $1.3.
May 14 '24
Burke Steven Keith filed to sell 695,840 shares at $1.6.
March 1 '24
Hadas Nicole R. filed to sell 663,259 shares at $1.6.
March 1 '24
Dahan Michel filed to sell 706,932 shares at $1.6.
March 1 '24

What is the Market Cap of Akebia Therapeutics?

The Market Cap of Akebia Therapeutics is $264M.

How Many People Work at Akebia Therapeutics?

As of our latest update, Akebia Therapeutics employed approximately 426 people worldwide. However, it's important to note that Akebia Therapeutics' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Akebia Therapeutics' revenue per employee?

$438,282. To calculate Akebia Therapeutics' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Akebia Therapeutics?

Currently, the price of one share of Akebia Therapeutics stock is $1.31.

How can I analyze the AKBA stock price chart for investment decisions?

The AKBA stock price chart above provides a comprehensive visual representation of Akebia Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Akebia Therapeutics shares. Our platform offers an up-to-date AKBA stock price chart, along with technical data analysis and alternative data insights.

Does AKBA offer dividends to its shareholders?

As of our latest update, Akebia Therapeutics (AKBA) does not offer dividends to its shareholders. Investors interested in Akebia Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Akebia Therapeutics?

Some of the similar stocks of Akebia Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.